Marico Q1 FY26 revenue rose 23%; resurfacing August move to raise Plix maker Satiya stake to 60%
Marico reported Q1 FY26 consolidated revenue of Rs 3,259 crore, up 23.3% year-on-year, while net profit rose 8.2% to Rs 513 crore. India revenue grew 27.2%, and the company had increased its fully diluted stake in Plix maker Satiya Nutraceuticals to 60% in early August, deepening its wellness portfolio.
What happened
Marico posted Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by a 27.2% rise in India revenue. It increased its stake in Plix maker Satiya
Key facts
- Q1 FY26 consolidated net profit rose 8.2% YoY to Rs 513 crore from Rs 474 crore
- Revenue from operations rose 23.31% to Rs 3,259 crore from Rs 2,643 crore
- Total income was Rs 3,315 crore, including Rs 56 crore other income
- Total expenses rose to Rs 2,659 crore from Rs 2,075 crore
- India revenue rose 27.17% to Rs 2,495 crore from Rs 1,962 crore
- International revenue rose 12.91% to Rs 764 crore from Rs 681 crore
- India segment PBT was Rs 469 crore; international segment PBT was Rs 213 crore
- Marico increased its Satiya Nutraceuticals stake to 60% on a fully diluted basis
Why this matters
Raising its Satiya Nutraceuticals stake to 60% gives Marico greater control over Plix and reinforces a strategy of building scale in high-growth wellness categories.
What to watch
- Whether India volume growth remains positive after the 27.2% revenue-growth quarter and how much growth is price versus volume.
- Sequential gross-margin and EBITDA-margin trends, particularly against copra, edible-oil, crude-derived packaging and currency movements.
- Plix/Satiya sales growth, distribution expansion, repeat purchase metrics and profitability after Marico raises its stake to 60%.
- Advertising and promotion spending as a percentage of sales, indicating whether wellness scale-up is becoming more costly.
- Rural-demand recovery, urban discretionary demand and competitive actions from FMCG, D2C nutrition and beauty/wellness players.
- Any further stake purchases, earn-out obligations or new wellness acquisitions that affect capital allocation and minority-interest accounting.
- Expand Plix/Satiya products into Marico's general trade, modern trade and e-commerce distribution network while retaining the brand's digital-native positioning.
- Increase wellness portfolio investments in protein, supplements, healthy snacking and preventive-health adjacencies, potentially including further bolt-on acquisitions.
- Use premiumisation and innovation in core India brands to sustain growth as pricing comparisons become more demanding.
- Prioritise margin management through copra, edible-oil and packaging-cost hedging, selective pricing and advertising-spend optimisation.
- Provide clearer disclosure on Satiya revenue, profitability, integration milestones and the share of premium/wellness sales to support the strategic narrative.